• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Rick E Winningham - Articles and news items

GlaxoSmithKline logo

GSK and Theravance announce initiation of phase III programme with fixed dose triple combination treatment FF/UMEC/VI in patients with COPD

Industry news / 16 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease…

GlaxoSmithKline logo

Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

Industry news / 4 July 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases…

GlaxoSmithKline logo

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS®

Industry news / 14 March 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies…

GlaxoSmithKline logo

Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® study to understand mortality and morbidITy (SUMMIT) in COPD

Industry news / 14 March 2014 / GlaxoSmithKline

GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment…

GlaxoSmithKline logo

RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD

Industry news / 18 November 2013 / GlaxoSmithKline

RELVAR® ELLIPTA® is now licensed across 31 European countries…

GlaxoSmithKline logo

FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD

Industry news, News / 10 September 2013 / GlaxoSmithKline

GSK and Theravance, Inc. announced that the PADAC to the US FDA voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol…

GlaxoSmithKline logo

BREO™ ELLIPTA™ gains US approval for the treatment of COPD

Industry news, News / 10 May 2013 / GlaxoSmithKline

GlaxoSmithKline and Theravance announced that the US FDA has approved BREO™ ELLIPTA™…

GlaxoSmithKline logo
GlaxoSmithKline logo

GSK and Theravance announce initial outcomes from pivotal Phase III studies

Industry news, News / 9 January 2012 / GlaxoSmithKline

GSK and Theravance, Inc. announced the completion of the phase III registration programme…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +